Revenue Update on BioPharmX Corp(NYSEMKT:BPMX)

BioPharmX Corp(NYSEMKT:BPMX) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Sep 12, 2016. Company reported revenue of $19.00K. Analysts estimated a revenue of $70.00K. Earnings per share were $-0.16. Analysts had estimated an EPS of $-0.17.

BioPharmX Corp (BPMX) shares turned negative on Tuesdays trading session with the shares closing down -0.01 points or -1.43% at a volume of 32,966. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $0.7. The peak price level was also seen at $0.7 while the days lowest was $0.66. Finally the shares closed at $0.69. The 52-week high of the shares is $2.75 while the 52-week low is $0.5. According to the latest information available, the market cap of the company is $22 M.

Several Insider Transactions has been reported to the SEC. On Aug 16, 2016, Resources Inc Franklin (10% owner) purchased 484,615 shares at $0.65 per share price.Also, On Jan 15, 2016, Stephen Morlock (director) purchased 12,000 shares at $1.52 per share price.

BioPharmX Corporation is a specialty pharmaceutical company focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter or OTC products that address markets in women’s health and dermatology. The Company’s portfolio of product candidates includes two clinical stage product candidates: BPX01 a topical antibiotic for the treatment of acne and BPX03 a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition or FBC and cyclic mastalgia. The Company’s commercial product VI2OLET iodine is an OTC dietary supplement molecular iodine tablet that promotes breast health and is for the alleviation of benign breast pain associated with fibrocystic breast condition or FBC. The Company has one wholly owned subsidiary BioPharmX Inc.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

BioPharmX Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on BioPharmX Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.